Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC) by Pischon, Tobias et al.
920                                                                                  
%DFNJURXQG  Body weight and body mass  index (BMI)  are
positively  related  to  risk  of  colon  cancer  in  men,  whereas
weak  or  no  associations  exist  in  women.  This  discrepancy
may  be  related  to  differences  in  fat  distribution  between
sexes or to the use of hormone replacement therapy (HRT)
in  women.    0HWKRGV  We  used  multivariable  adjusted  Cox
proportional  hazards  models  to  examine  the  association
between  anthropometric  measures  and  risks  of  colon  and
rectal cancer among 368  277 men and women who were free
of  cancer at  baseline  from nine  countries  of  the  European
Prospective  Investigation  Into  Cancer  and  Nutrition.  All
statistical tests were two-sided.  5HVXOWV During 6.1 years of
follow-up, we identi¿ ed 984 and 586 patients with colon and
rectal cancer,  respectively. Body weight and BMI were sta-
tistically  signi¿ cantly  associated  with  colon  cancer  risk  in
men  (highest  versus  lowest  quintile  of  BMI,  relative  risk
[RR]  =  1.55,  95%  con¿ dence  interval  [CI]  =  1.12  to  2.15;
3  trend  = .006) but not in women. In contrast, comparisons of
the highest to the lowest quintile showed that several anthro-
pometric  measures,  including  waist  circumference  (men,
RR = 1.39, 95% CI = 1.01 to 1.93;  3  trend  = .001; women, RR =
1.48, 95% CI = 1.08 to 2.03;  3  trend  = .008), waist-to-hip ratio
(WHR; men, RR = 1.51, 95% CI = 1.06 to 2.15;  3  trend  = .006;
women, RR = 1.52, 95% CI = 1.12 to 2.05;  3  trend  = .002), and
height (men, RR = 1.40, 95% CI = 0.99 to 1.98;  3  trend  = .04;
women, RR = 1.79, 95% CI = 1.30 to 2.46;  3  trend  <.001) were
related  to  colon  cancer  risk  in  both  sexes.  The  estimated
absolute risk of developing colon cancer within 5 years was
203 and 131 cases per 100  000 men and 129 and 86 cases per
100  000 women in the highest and lowest quintiles of WHR,
respectively.  Upon  further  strati¿ cation,  no  association  of
waist circumference and WHR with risk of colon cancer was
observed  among  postmenopausal  women  who  used  HRT.
None of  the  anthropometric  measures  was statistically  sig-
ni¿ cantly  related  to  rectal  cancer.    &RQFOXVLRQV  Waist cir-
cumference and WHR, indicators of abdominal obesity, were
strongly associated with colon cancer risk in men and women
in this population. The association of abdominal obesity with
colon cancer risk may vary depending on HRT use in post-
menopausal women; however, these ¿ ndings require con¿ r-
mation in future studies.  [J Natl Cancer Inst 2006;98: 920  31 ]
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 Body  Size  and  Risk  of  Colon  and  Rectal  Cancer  in  the  European
Prospective  Investigation  Into  Cancer  and  Nutrition  (EPIC)
Tobias  Pischon ,  Petra H.  Lahmann ,  Heiner  Boeing ,  Christine  Friedenreich ,  Teresa  Norat ,
Anne  Tj nneland ,  Jytte  Halkjaer ,  Kim  Overvad ,  Fran oise  Clavel-Chapelon ,  Marie-Christine
Boutron-Ruault ,  Gregory  Guernec ,  Manuela M.  Bergmann ,  Jakob  Linseisen ,  Nikolaus  Becker ,
Antonia  Trichopoulou ,  Dimitrios  Trichopoulos ,  Sabina  Sieri ,  Domenico  Palli ,  Rosario
Tumino ,  Paolo  Vineis ,  Salvatore  Panico ,  Petra H. M.  Peeters ,  H. Bas  Bueno-de-Mesquita  ,
Hendriek C.  Boshuizen ,  Bethany  Van Guelpen ,  Richard  Palmqvist ,  G ran  Berglund ,  Carlos
Alberto  Gonzalez ,  Miren  Dorronsoro ,  Aurelio  Barricarte ,  Carmen  Navarro ,  Carmen  Martinez ,
J. Ram n  Quir s ,  Andrew  Roddam ,  Naomi  Allen ,  Sheila  Bingham ,  Kay-Tee  Khaw ,  Pietro
Ferrari ,  Rudolf  Kaaks ,  Nadia  Slimani ,  Elio  Riboli
 A possible association between body size and risk of colorec-
tal  cancer  has  been  examined  in  many  epidemiologic  studies
( 1  30 ) . In general, body weight and body mass index (BMI) have
been found to be positively related to risk of colon cancer in men,
whereas weaker or no associations have been reported for women
( 1  30 ) . Among the smaller number of studies that examined as-
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body weight or BMI  (2  5 , 12 , 17 , 27 , 30 ) . The reasons for the ap-
parent discrepancy in the association of body weight with colon
cancer risk between men and women are unclear.
 One  potential  reason  for  the  discrepancy  is  that  men  and
women have different body compositions. Fat makes up a lower
percentage of the body mass of men (approximately 20%) than of
women (approximately 30%). The relationship of body weight to
fat  distribution  also  differs  between  men  and  women.  Higher
body weight  is  more  closely  related  to  abdominal  obesity  than
lower body obesity  in  men and  more closely related to  gluteo-
femoral  obesity  than  to  abdominal  obesity  in  women.  Further-
more,  upper-body  fat  has  been  shown  to  be  more  strongly
associated with metabolic abnormalities than lower-body obesity
( 31 , 32 ) . However, only a few prospective studies have examined
the association of body fat distribution  as reÀ ected by waist and
hip circumference  and colon cancer risk  ( 11 , 13 , 14 , 19 , 21 ) . Also,
in most of these studies  (11 , 13 , 14 ) , waist and hip circumference
were self-reported rather than measured.
 Other reasons for sex differences in the association between
adiposity and colon cancer risk may be related to use of hormone
replacement  therapy  (HRT)  in  postmenopausal  women.  Post-
menopausal  HRT use  has been associated with reduced risk of
colon  cancer  in  observational  and  intervention  studies   (33  36 )
and has been shown to affect the association between body weight
and postmenopausal breast cancer  (37 ) ; however, little is known
about associations with colon cancer  (20 ) .
The aim of this study was to examine the association between
anthropometric measures, including waist and hip circumference,
and risk of  colon and rectal  cancer in participants of  the Euro-
pean Prospective Investigation Into Cancer and Nutrition (EPIC),
a large European cohort study. In particular, we examined whether
body fat distribution is related to risk of colon and rectal cancer.
Furthermore, we aimed to examine whether the associations dif-
fer  among  postmenopausal  women  who  were  HRT  users  and
those who were not.
S UBJECTS AND M ETHODS
Study Population
 The EPIC is an ongoing multicenter prospective cohort study
designed primarily to investigate the relationship between  nutrition
and cancer. The EPIC study consists of subcohorts  recruited in 23
administrative  centers  in  10  European  countries   Denmark,
France, Germany, Greece, Italy, The Netherlands, Norway, Spain,
Sweden, and the United Kingdom. The 519  978 eligible male and
female participants were aged between 25 and 70 years at enroll-
ment (1992  2000) and were recruited from the general population
residing in a given geographic area (i.e., town or province). Ex-
ceptions were the French cohort (based on  female members of a
health insurance plan for school employees), the Utrecht cohort in
The Netherlands (based on women attending breast cancer screen-
ing), the Ragusa cohort in Italy (based on blood donors and their
spouses), and the Oxford cohort in the United Kingdom (includ-
ing mainly vegetarian volunteers and healthy eaters). Eligible sub-
jects  were  invited  to  participate  in  the  study,  and  those  who
accepted gave written informed consent and completed question-
naires on their diet, lifestyle, and medical history. Subjects were
then  invited  to  a  center  to  provide  a  blood  sample  and  to  have
 anthropometric  measurements  taken.  The  methods  have  been
 reported in full  by Riboli  et  al.   (38 , 39 )  .  Approval  for  this study
was obtained from the ethical review boards of the International
Agency  for  Research  on  Cancer  and  from  all  local  institutions
where subjects had been recruited for the EPIC study.
 This study is based on 495 417 participants without prevalent
cancer at any site at baseline, as reported on the lifestyle ques-
tionnaire or based on information from the cancer registries. We
excluded the Umea, Sweden, cohort (n = 24  811) because partici-
pants did not provide information on leisure time physical activ-
ity that was compatible with the other EPIC questionnaires. We
also excluded subjects without measured body height or weight
and thus excluded the cohorts from Norway (n = 35  956), 48  960
participants from the French cohorts, and 7903 participants from
the  other  cohorts.  For  the    health-conscious   group  based  in
 Oxford (UK), linear regression models were used to predict sex-
and  age-speci¿ c  values  from  subjects  with  both  measured  and
self-reported  body  measures,  as  previously  described   ( 40 , 41 ) .
We  further  excluded  2166  participants  with  missing  question-
naire data or with missing dates of diagnosis or follow-up and, to
reduce the impact on the analysis of implausible extreme values,
the 7344 participants who were in the top or bottom 1% of the
ratio of energy intake to estimated energy requirement that was
calculated from body weight, height, and age  ( 42 ) . Therefore, the
study included a total of 368  277 participants.
Assessment of Endpoints
 Incident  colorectal  cancer  case  patients  were  identi¿ ed by
population  cancer  registries  (Denmark,  Italy,  The  Netherlands,
Spain,  Sweden,  the  United  Kingdom)  or  by  active  follow-up
(France, Germany, Greece), depending on the follow-up system
in each of the participating centers. Active follow-up used a com-
bination of methods, including health insurance records, cancer
and  pathology  registries,  and  direct  contact  with  participants
or next of kin. Mortality data were also obtained from cancer or
mortality  registries  at  the regional  or  national  level.  Follow-up
began at the date of enrollment and ended at  either the date of
diagnosis of colorectal cancer, death, or last complete follow-up.
By  April  30,  2004,  for  the  centers  using  record  linkage  with
 cancer registry data, complete follow-up was available through
December 31, 1999 (Turin, Italy); June 30, 2000 (Bilthoven, The
Netherlands); December 31, 2000 (Asturias and Murcia, Spain;
Cambridge,  UK);  December  31,  2001  (Oxford,  UK;  Malm ,
Sweden; Florence, Naples, Ragusa, and Varese, Italy); December
31,  2002 (Granada, Navarra, and San Sebastian,  Spain;  Aarhus
and  Copenhagen,  Denmark);  and  June  30,  2003  (Utrecht,  The
Netherlands).  For  the  centers  using  active  follow-up,  the  last
 contact dates were June 30, 2002 (France); November 19, 2002
(Greece); December 16, 2003 (Heidelberg, Germany); and March
11,  2004  (Postdam,  Germany).  Mortality  data  were  coded  fol-
lowing the rules of the 10th revision of the International Statisti-
cal  Classi¿ cation  of  Diseases,  Injuries  and  Causes  of  Death
(ICD-10), and cancer incidence data were coded according to the
2nd  revision  of  the  International  Classi¿ cation  of  Diseases  for
Oncology (ICD-O-2). We included all patients with colon (C18)
and rectal (C19, C20) cancer.
 Assessment  of  Anthropometric  Data,  Diet,  and
Lifestyle  Factors
 Weight  and height were measured  with subjects wearing no
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the nearest 0.1, 0.5, or 1.0 cm, respectively  ( 40 ) . BMI was calcu-
lated as weight in kilograms divided by height in meters squared
(kg/m 2 ). Waist circumference was measured either at the narrow-
est torso circumference (France; Italy; Utrecht, The Netherlands;
Denmark)  or  at  the  midpoint  between  the  lower  ribs  and  iliac
crest (Bilthoven, The Netherlands; Potsdam, Germany; Malm ,
Sweden;  Oxford,  UK,  general  population).  In  Spain;  Greece;
Heidelberg,  Germany;  and  Cambridge,  UK,  a  combination  of
methods was used, although most participants were measured at
the narrowest torso circumference. Hip circumference was mea-
sured at the widest circumference (France; Italy; Spain; Bilthoven,
The Netherlands; Greece; Malm , Sweden) or over the buttocks
(the  United  Kingdom;  Utrecht,  The  Netherlands;  Germany;
 Denmark). Results of the present analyses for waist and hip cir-
cumference  were  similar  for  the  different  assessment  methods.
Waist  and  hip  circumference  measurements  were  missing  for
3869 (1.05%) and 6399 (1.74%) participants, respectively, who
were  excluded  for  analyses  on  these  variables.  For  this  study,
body weight and waist and hip circumference were corrected, as
described in detail elsewhere  ( 40 ) , to reduce heterogeneity due to
protocol differences in clothing worn during measurement.
 Diet during the 12 months before enrollment was measured by
country-speci¿ c validated questionnaires  ( 43 ) . Most centers adopted
a  self-administered  dietary  questionnaire  covering  88   266  food
items. In Greece, Spain, and Ragusa, Italy, the questionnaire was ad-
ministered at a personal interview. In Malm , Sweden, a question-
naire combined with a food record was used. Country-speci¿ c food
composition tables were used to calculate nutrient intakes  (44 ) .
Recreational and household activity was computed as average
metabolic  equivalent-hours  (MET-hr),  based  on  the  types  and
durations of activities reported separately for summer and winter
on the baseline questionnaires. The reported activities included
walking,  cycling,  gardening,  sports  and  exercise,  housework,
home repair (do-it-yourself activities), stair climbing, and vigor-
ous  recreational  activity.  Each  type  of  activity  was  assigned  a
speci¿ c  MET  value  according  to  Ainsworth  et  al.   (45 ) . Occu-
pational  activity  was  coded  as  sedentary  occupation,  standing
 occu pation,  manual work,  heavy manual  work,  unemployed, or
missing, as reported on the questionnaire. To create a variable for
total physical activity, subjects were cross-classi¿ ed on the basis
of  sex-  speci¿ c  quartiles  of  recreational  and  household  activity
and on categories of occupational work and were coded as inac-
tive, moderately inactive, moderately active, active, and missing.
Information on sociodemographic and lifestyle characteristics
and  medical  history  was  obtained  from  standardized  question-
naires  at  study entry  (38 )  .  Women were classi¿ ed according to
menopausal status at enrollment on the basis of an algorithm that
accounts  for  complete and combined information on menstrual
status/history, type of menopause (natural, bi-/unilateral oopho-
rectomy,  hysterectomy),  and  use  of  oral  contraceptives  and
menopausal  hormones  (37 )  .  Current  HRT use  refers  to  the  use
of  menopausal  hormones at  the  time of  recruitment  as  derived
from  the  country-speci¿ c  questionnaires  or  during  interviews,
and   includes  estrogen  alone  and  combined  estrogen   progestin
pre parations. The prevalence of HRT use within EPIC has been
described in detail elsewhere  ( 46 ) .
Statistical Analyses
 We  analyzed  the  association  between  anthropometric  vari-
ables and risks of colon and rectal cancer separately for men and
women by calculating relative risks (RRs) as incident rate ratios
using Cox proportional hazards models. Age was used as the un-
derlying  time  variable,  with  entry  and  exit  time  de¿ ned  as  the
subject s age at recruitment and age at colorectal cancer diagno-
sis or censoring, respectively. Subjects were grouped into quin-
tiles  on  the  basis  of  the  anthropometric  variables  of  the  entire
male  or  female  cohorts,  respectively.  We also  performed  addi-
tional  analyses  by  grouping  participants  into  prede¿ ned well-
 established  categories  for  BMI  (<25,  25   <30,  or    30 kg/m 2 ),
waist circumference (<102 or   102 cm in men, and <88 or   88
in women), and waist-to-hip ratio (WHR; <0.95 or   0.95 in men;
and <0.80 or   0.80 in women)  ( 47 , 48 ) . Models were strati¿ ed by
age at recruitment and by study center to reduce sensitivity to any
violations  of  the  proportional  hazards  assumption.  We  further
 adjusted the analysis for smoking status (never, past, current, or
unknown), education (no school degree or primary school, tech-
nical or professional school, secondary school, university degree,
or  unknown),  alcohol  consumption  (grams/day,  continuous),
physical  activity  (inactive,  moderately  inactive,  moderately  ac-
tive, active, missing), ¿ ber intake (grams/day, continuous), and
consumption of red and processed meat,  ¿ sh and shell¿ sh, and
fruits  and  vegetables  (all  grams/day,  continuous).  Analyses  of
weight,  waist  and  hip  circumference,  and  WHR  were  also  ad-
justed for body height, and, in additional models, for body weight.
We also performed additional analyses that adjusted for total en-
ergy intake; however, because the overall results did not change
substantially, we did not include energy intake in our analysis. To
test for linear trend across categories, we used the median anthro-
pometric  variable  within  quintiles  as  a  continuous  variable.  In
separate analyses we included body size measures as continuous
variables in the models to estimate the relative risk of colon and
rectal cancer per unit increase in each anthropometric variable.
Differences in the associations across study centers were assessed
with  the  chi-square  test  using  heterogeneity  statistics  that  are
based on the inverse variance method  ( 49 ) . To test for differences
between sexes, we performed the analysis with men and women
combined  and  added  an  interaction  term to  the  model.  Among
postmenopausal women we further strati¿ ed the analysis by HRT
use and tested for differences between HRT and non-HRT users
by adding an interaction term. The proportional hazards assump-
tion was checked by adding an interaction term of the main expo-
sure variable with time to each model. The interaction term was
not statistically signi¿ cant (at the 5% level) in any model. Abso-
lute risks were estimated from the survivor function with covari-
ates (including age) set to sex-speci¿ c mean levels.
All  P values presented are two-tailed, and  P <.05 was consid-
ered  statistically  signi¿ cant.  Analyses  were  performed  using
SAS 9.1 (SAS Institute, Cary, NC).
R ESULTS
 A total of 368  277 participants were monitored for an average
6.1  1.7 years,  for a total of 2  254  727 person-years (  Table 1 ).
During follow-up, 1570 members of the cohort were diagnosed
with  colorectal  cancer  (984  colon,  586  rectum).  Mean  age  at
baseline was 51.7 years; 64.8% of participants were female.
We compared the age-standardized characteristics of the EPIC
participants  at  baseline  by  BMI  quintile  for  men  and  women,
 respectively  (men  and  women  in  higher  BMI  categories  were
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consumption was positively related to BMI in men but inversely
related to  BMI in women.  Both men and women in  the  higher
BMI categories were less likely than those in the lower BMI cat-
egories  to  be current  smokers  and more likely to  have a lower
education  level.  Men  in  the  higher  BMI  categories  were  less
likely to be never smokers,  whereas women in the higher BMI
categories were more likely to be never smokers.  Among post-
menopausal women, HRT use was more common among leaner
women. Subjects in the higher BMI categories had higher intake
of all food groups analyzed (fruits and vegetables, ¿ sh and shell-
¿ sh, and meat and meat products) than subjects in the lower BMI
categories. WHR was more closely related to BMI in men than in
women. Age-adjusted Pearson correlation coef¿ cients for the as-
sociation  of  BMI  with  waist  and  hip  circumference  and  WHR
were  r = 0.86,  r = 0.77, and  r = 0.56, respectively, for men, and
r  =  0.85,   r  =  0.86,  and   r  =  0.43,  respectively,  for  women  (all
P <.001).
 We examined relative risks of colon cancer by quintile of an-
thropometric  variables  in  men  and  women  (  Table  3  ).  In  both
sexes, there was a statistically signi¿ cant trend of increasing rela-
tive  risks  of  colon  cancer  across  quintile  of  height  (for  men
[  180.5 cm versus < 168.0 cm], RR = 1.40, 95% CI = 0.99 to
1.98;   P trend  = 0.04;  for women [  167.5 cm versus <156.0 cm],
RR = 1.79, 95% CI = 1.30 to 2.46;  P trend <.001;  Table 3 ). On a
continuous scale,  a  5-cm higher  body  height  was related  to  an
increased risk of colon cancer in both men (RR = 1.09, 95% CI =
1.01 to 1.18;  P = .02) and women (RR = 1.12, 95% CI = 1.04 to
1.20;  P = .003) ( P = .33 for difference in the association between
men and women).
Among men, weight and BMI were associated with a higher
risk  of  colon  cancer  (weight    90.0  kg  versus  <71 kg,  RR  =
1.43, 95% CI = 1.02 to 2.02;  P trend = .007; BMI   29.4 kg/m2
versus <23.6 kg/m 2 , RR = 1.55, 95% CI = 1.12 to 2.15;  P trend =
.006;  Table 3 ) but not among women. Per unit increase, higher
body weight and BMI were associated with colon cancer risk
in men (per 5 kg of higher body weight, RR = 1.09, 95% CI =
1.04 to 1.13;  P<. 001; per kg/m 2 higher BMI, RR = 1.05, 95%
CI = 1.02  to  1.08;   P<.  001).  However,  among women the as-
sociation was weaker and only marginally statistically signi¿ -
cant (per 5 kg higher body weight, RR = 1.04, 95% CI = 1.00
to 1.08;  P = .03;  P = .35 for difference to men; per kg/m 2 higher
BMI, RR = 1.02, 95% CI = 1.00 to 1.04;  P = .07;  P = .04 for
difference to men).
 In both sexes,  waist  circumference was positively related to
risk  of  colon  cancer  (for  men  [   103.0  cm  versus  <86.0  cm],
RR  =  1.39,  95%  CI  =  1.01  to  1.93;   P trend  =  .001;  for  women
[  89.0 cm versus <70.2 cm], RR = 1.48, 95% CI = 1.08 to 2.03;
P trend = .008)). Per 5 cm higher waist circumference, the relative
risk for men was 1.10 (95% CI = 1.05 to 1.56;  P <.001) and for
women was 1.07 (95% CI = 1.03 to 1.12;  P<. 001;  P  = .48 for
difference between men and women). In contrast, hip circumfer-
ence  was  statistically  signi¿ cantly  positively  related  to  colon
cancer in  men (per 5 cm higher hip circumference, RR = 1.12,
95% CI = 1.05 to 1.21;  P = .002) but not in women (RR = 1.04,
95% CI = 0.99 to 1.09;  P = .10;  P = .15 for difference between
men and women).
 WHR was positively related to colon cancer risk in both men
(RR per 0.1 higher WHR, RR = 1.24, 95% CI = 1.05 to 1.46;  P =
.01) and women (per 0.1 higher WHR, RR = 1.24, 95% CI = 1.10
to  1.39;   P <.001) ( P  =  .92  for  difference  between  men  and
women). In fact, of all anthropometric parameters, WHR showed
the strongest association with colon cancer (highest versus low-
est quintile for men, RR = 1.51, 95% CI = 1.06 to 2.15;  P trend =
.006;  for  women,  RR =  1.52,  95%  CI  =  1.12  to  2.05;   P trend =
.002).  The  estimated  absolute  5-year  rate  of  developing  colon
cancer per 100  000 subjects were, for men, 203 cases (95% CI =
155 to 250) in the highest quintile of WHR and 131 cases (95%
CI = 91 to 170) in the lowest and, for women, 129 cases (95%
CI = 102 to 156) in the highest quintile of WHR and 86 (95% CI =
63  to  108)  in  the  lowest.  We  found  no  statistically  signi¿ cant
heterogeneity across study centers for any of the associations of
the  anthropometric  measures  with  colon  cancer  risk  in  men or
women ( P heterogeneity = 0.34  0.92). We examined the consistency
of our ¿ ndings by excluding 239 patients diagnosed during the
¿ rst  2  years  of  follow-up,  to  eliminate  the  possible  effects  of
changes in body weight and fat distribution in the prediagnostic
disease phase. After exclusion, the relative risk of colon cancer
per 0.1 higher WHR was 1.26 (95% CI = 1.04 to 1.52;  P = .02) in
men, and 1.25 (95% CI = 1.09 to 1.42 ; P = .001) in women. Thus,
these patients did not bias the results.
There was no statistically signi¿ cant association of any of the
anthropometric measures with rectal cancer ( Table 4 ). The appar-
ent nonlinear relationship for WHR in men may be due to the low
number of case patients in the reference category.
 We  further  divided  participants  into  groups  based  on  well-
 established  risk  categories  for  BMI,  waist  circumference,  and
Table 1.  Cohort characteristics, the European Prospective Investigation into Cancer and Nutrition
Cohort size, n  Mean age, y  Person-years  Colon cancer, n  Rectal cancer, n  Mean BMI, kg/m 2 *  Mean WHR *
Country Men Women Men Women Men Women Men Women Men Women Men Women Men Women
France 0 19  752 0 52.8 0 167  895 0 53 0 8 0 23.2 0 0.777
Italy 13  895 30  325 50.2 50.7 74  170 187  029 44 64 17 26 26.5 25.7 0.936 0.797
Spain 14  986 24  616 50.7 48.3 102  413 162  305 39 39 26 15 28.5 28.4 0.951 0.829
United
Kingdom
22  542 50  998 53.1 47.7 118  468 277  133 92 91 33 54 25.4 24.5 0.914 0.769
The
Netherlands
9890 27  484 43.2 51.0 50  057 181  701 11 100 11 46 26.0 25.2 0.926 0.789
Greece 10  529 14  922 52.9 53.3 38  776 55  514 7 6 7 5 27.9 28.4 0.955 0.814
Germany 21  340 27  712 52.4 49.1 124  150 162  055 58 44 53 16 27.0 25.8 0.944 0.800
Sweden 10  263 14  010 59.0 57.3 79  008 105  781 48 58 46 42 25.6 24.4 0.933 0.782
Denmark 26  286 28  727 56.6 56.7 174  439 193  832 122 108 102 79 26.4 25.0 0.949 0.796
Total 129  731 238  546 52.8 51.1 761  482 1  493  245 421 563 295 291 26.6 25.5 0.939 0.792
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WHR,  respectively.  Compared  with  nonoverweight  subjects
(BMI <  25  kg/m 2  ),  the  relative  risk  for  colon  cancer  was  1.00
(95% CI  =  0.80  to  1.26)  for  overweight  men (BMI  =  25   29.9
kg/m 2 ) and 1.16 (95% CI = 0.96 to 1.40) for overweight women,
and  1.41  (95% CI  =  1.06  to  1.88;   P trend  =  .03)  for  obese  men
(BMI   30 kg/m 2 ) and 1.07 (95% CI = 0.82 to 1.38;  P trend = .41)
for obese women. Among men, those with a waist circumference
of at least 102 cm had a higher risk for colon cancer than those
with a waist circumference of less than 102 cm (RR = 1.37, 95%
CI = 1.10 to 1.70;  P = .004), whereas among women, risk did not
differ between those with a waist circumference at least  88 cm
versus less than 88 cm (RR = 1.18; 95% CI = 0.97 to 1.43;  P =
.10).  However,  men in  the  higher  WHR category  had a  higher
risk of colon cancer (  0.95 versus <0.95, RR = 1.44, 95% CI =
1.17 to 1.76;  P <.001), and the same was true for women (  0.80
versus <0.80, RR = 1.27, 95% CI = 1.06 to 1.51;  P = .008). The
absolute 5-year rate of colon cancer per 100  000 individuals was
206 cases (95% CI = 167 to 245) for men with a WHR of at least
0.95 and 144 cases (95% CI = 117 to 171) for men with a WHR
less than 0.95, 115 cases (95% CI = 95 to 135) for women with a
WHR of at  least  0.80,  and 91 cases  (95% CI  =  76  to  106)  for
women with a WHR less than 0.80.
In analyses that also adjusted for body weight, waist and hip
circumference and WHR were not statistically signi¿ cantly re-
lated to  risk of  colon  cancer  in  men,  whereas  WHR remained
statistically signi¿ cant in women ( Table 5 ). Results were simi-
lar  when  we  adjusted  these  analyses  for  BMI  instead  of  for
weight and height (highest versus lowest WHR quintile adjusted
Table 2.  Characteristics of study participants in the European Prospective Investigation into Cancer and Nutrition by body mass index (BMI) *
Men, quintile of BMI, kg/m 2  Women, quintile of BMI, kg/m2
1 2 3 4 5 1 2 3 4 5
Range <23.6 23.6  25.3 25.4  27.0 27.1  29.3   29.4 <21.7 21.7  23.6 23.7  25.7 25.8  28.8   28.9
Characteristic Mean 22.0 24.6 26.3 28.2 32.0 20.2 22.7 24.7 27.2 32.7
N 25  946 25  948 25  947 25  956 25  934 47  736 47  683 47  706 47  714 47  707
Mean age, y 50.3 52.6 53.3 53.8 54.0 46.7 49.7 51.7 53.3 54.1
Mean alcohol
intake,  g/day
20.0 21.3 22.2 23.3 24.7 9.6 9.6 8.9 7.9 6.0
Smoking status  , %
Never smoker 33.9 32.0 30.3 27.9 26.5 52.7 52.9 53.5 56.8 62.6
Past smoker 29.9 36.1 39.1 41.1 42.1 23.0 25.0 24.6 22.7 19.8
Current smoker 34.9 30.4 29.0 29.5 29.9 23.1 21.2 21.1 19.7 16.6
Education  , %
No school degree or
primary  school
21.7 24.8 28.5 35.4 42.5 14.6 19.4 26.5 35.7 47.1
Technical or
professional  school
24.3 25.2 25.8 25.3 23.7 24.2 26.2 26.0 24.6 21.3
Secondary school 15.7 16.0 15.2 13.8 12.9 24.7 23.2 21.6 19.0 15.3
University degree 34.7 30.8 27.4 22.6 17.8 31.6 26.2 21.3 16.2 11.2
Total physical
activity  , %
Inactive 19.8 20.4 20.2 19.9 19.9 19.0 17.8 16.2 14.0 11.4
Moderately inactive 28.9 28.2 28.4 28.9 29.1 37.1 33.4 30.9 28.5 26.6
Moderately active 35.7 34.9 35.5 35.3 36.2 34.8 38.5 42.2 46.9 51.5
Active 13.1 13.9 13.3 13.6 13.1 8.0 9.0 9.2 9.2 9.2
Menopausal status  , %
Premenopausal           33.3 33.6 33.8 33.8 33.9
Perimenopausal           13.1 13.0 12.6 12.4 11.9
Postmenopausal           45.9 45.6 45.6 45.0 44.6
Surgical
postmenopausal
         2.4 2.8 3.1 3.8 4.7
HRT use among
postmenopausal
women  , %
No           69.6 71.4 73.7 78.1 84.4
Yes           28.3 26.4 24.2 20.2 14.2
Mean weight, kg 68.2 75.5 80.1 85.2 95.7 54.1 60.3 64.8 70.5 83.1
Mean height, cm 175.8 175.2 174.5 173.8 172.7 163.3 162.8 162.0 160.9 159.4
Mean waist
circumference, cm
83.7 89.7 93.8 98.4 107.4 69.2 74.0 78.3 83.9 95.1
Mean hip
circumference, cm
94.2 97.9 100.3 103.0 108.8 91.9 96.3 99.7 104.0 113.4
Mean waist-to-hip ratio 0.89 0.92 0.94 0.96 0.99 0.75 0.77 0.79 0.80 0.84
Mean ¿ ber intake, g/day 24.6 24.4 24.4 24.7 25.1 22.9 22.8 22.7 22.7 23.0
Mean fruit and vegetable
intake,  g/day
393.0 417.2 434.3 465.2 496.5 466.2 477.2 485.9 507.8 538.3
Mean ¿ sh and shell¿ sh
intake,  g/day
34.9 37.1 38.9 41.1 43.4 29.2 30.7 31.7 33.2 34.2
Mean red and processed
meat  intake,  g/day
95.5 102.1 105.7 110.1 116.4 59.8 63.6 67.5 70.6 73.6
* All values except age, BMI, and number of subjects are age standardized. HRT = hormone replacement therapy.
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for BMI in men, RR = 1.19, 95% CI = 0.80 to 1.77;  P trend = .26;
in women, RR = 1.46, 95% CI = 1.06 to 2.01;  P trend = .01). Con-
versely, no statistically signi¿ cant association was observed for
BMI after adjustment for WHR among men or women.
 When  we  restricted  the  analysis  to  women  who  were  post-
menopausal  at  baseline  (including  424  postmenopausal  women
who developed colon cancer), the results were similar to those in
women overall (data not shown). Among postmenopausal women,
336 colon cancer patients (75.1%) reported no HRT use at base-
line, and 81 patients (23.3%) reported HRT use; for the remaining
7 patients, information on HRT use was unavailable. The positive
associations for waist circumference and WHR with risk of colon
cancer were restricted to postmenopausal women who did not use
HRT at baseline ( Table 6 ) (for difference between postmenopausal
women  with  and  without  HRT use  for  the  association  of  colon
cancer with waist circumference,  P = .05; and for the association
with WHR,  P = .19). HRT alone was not statistically signi¿ cantly
related to colon cancer risk in postmenopausal women.
D ISCUSSION
 In  this  large  prospective  cohort  study,  we  found  that  body
weight and BMI were statistically signi¿ cantly related to colon
Table 3.  Relative risks (RRs) and 95% con¿ dence intervals (CIs) of colon cancer across quintiles of anthropometric measures in the European Prospective











Height, cm Height, cm
<168.0 79 1 (Referent) 1 (Referent)  <156.0 80 1 (Referent) 1 (Referent)
168.0  172.4 84 1.09 (0.79 to 1.50) 1.10 (0.80 to 1.52)  156.0 159.9 106 1.34 (0.99 to 1.80) 1.33 (0.99 to 1.80)
172.5  176.1 86 1.14 (0.82 to 1.57) 1.16 (0.84 to 1.60)  160.0 163.2 141 1.72 (1.29 to 2.30) 1.71 (1.28 to 2.28)
176.2  180.4 91 1.26 (0.91 to 1.74) 1.29 (0.93 to 1.79)  163.3 167.4 128 1.68 (1.25 to 2.27) 1.66 (1.23 to 2.24)
 180.5 81 1.33 (0.95 to 1.87) 1.40 (0.99 to 1.98)    167.5 108 1.82 (1.33 to 2.50) 1.79 (1.30 to 2.46)
P trend  .06 .04    P trend  <.001 <.001
Weight, kg Weight, kg
<71.0 72 1 (Referent) 1 (Referent)  <56.9 83 1 (Referent) 1 (Referent)
71.0  76.9 68 0.94 (0.67 to 1.31) 0.91 (0.65 to 1.28)  56.9 62.0 100 1.20 (0.89 to 1.60) 1.14 (0.84 to 1.53)
77.0  82.7 79 1.12 (0.81 to 1.54) 1.06 (0.76 to 1.48)  62.1 67.4 108 1.19 (0.89 to 1.59) 1.10 (0.82 to 1.49)
82.8  89.9 93 1.33 (0.97 to 1.82) 1.24 (0.89 to 1.73)  67.5 74.9 137 1.35 (1.02 to 1.78) 1.23 (0.91 to 1.64)
 90.0 109 1.57 (1.16 to 2.13) 1.43 (1.02 to 2.02)    75.0 135 1.40 (1.06 to 1.86) 1.25 (0.93 to 1.70)
P trend  <.001 .007    P trend  .02 .14
BMI, kg/m 2  BMI, kg/m2
<23.6 64 1 (Referent) 1 (Referent)  <21.7 87 1 (Referent) 1 (Referent)
23.6  25.3 85 1.20 (0.86 to 1.66) 1.18 (0.85 to 1.63)  21.7 23.5 96 0.92 (0.69 to 1.23) 0.92 (0.68 to 1.23)
25.4  27.0 74 1.03 (0.74 to 1.45) 1.00 (0.71 to 1.41)  23.6 25.7 120 1.02 (0.77 to 1.35) 1.02 (0.77 to 1.35)
27.1  29.3 88 1.24 (0.89 to 1.72) 1.19 (0.85 to 1.66)  25.8 28.8 137 1.09 (0.83 to 1.44) 1.09 (0.83 to 1.45)
 29.4 110 1.64 (1.19 to 2.25) 1.55 (1.12 to 2.15)    28.9 123 1.04 (0.78 to 1.39) 1.06 (0.79 to 1.42)
P trend  .002 .006    P trend  .46 .40
Waist circumference, cm Waist circumference, cm
<86.0 63 1 (Referent) 1 (Referent)  <70.2 62 1 (Referent) 1 (Referent)
86.0  91.8 57 0.75 (0.53 to 1.08) 0.73 (0.50 to 1.04)  70.2 75.8 91 1.13 (0.81 to 1.56) 1.10 (0.80 to 1.52)
91.9  96.5 78 1.03 (0.74 to 1.44) 0.97 (0.69 to 1.36)  75.9 80.9 125 1.27 (0.93 to 1.73) 1.23 (0.90 to 1.68)
96.6  102.9 95 1.20 (0.87 to 1.66) 1.10 (0.79 to 1.53)  81.0 88.9 135 1.29 (0.95 to 1.76) 1.25 (0.91 to 1.70)
 103.0 125 1.56 (1.14 to 2.14) 1.39 (1.01 to 1.93)    89.0 149 1.53 (1.12 to 2.09) 1.48 (1.08 to 2.03)
P trend  <.001 .001    P trend  .004 .008
Hip circumference, cm Hip circumference, cm
<95.2 71 1 (Referent) 1 (Referent)  <93.7 83 1 (Referent) 1 (Referent)
95.2  98.9 62 0.93 (0.66 to 1.31) 0.90 (0.64 to 1.27)  93.7 97.9 90 1.03 (0.76 to 1.39) 0.99 (0.73 to 1.34)
99.0  101.9 97 1.13 (0.83 to 1.55) 1.08 (0.78 to 1.48)  98.0 101.9 137 1.16 (0.88 to 1.52) 1.09 (0.82 to 1.44)
102.0  105.9 76 1.36 (0.98 to 1.89) 1.27 (0.90 to 1.78)  102.0 107.9 108 1.10 (0.82 to 1.47) 1.02 (0.76 to 1.38)
 106.0 110 1.51 (1.11 to 2.06) 1.37 (0.99 to 1.90)    108.0 142 1.28 (0.97 to 1.70) 1.20 (0.89 to 1.60)
P trend  <.001 .01    P trend  .07 .19
WHR WHR
<0.887 48 1 (Referent) 1 (Referent)  <0.734 68 1 (Referent) 1 (Referent)
0.887  0.922 72 1.19 (0.83 to 1.72) 1.16 (0.80 to 1.68)  0.734 0.768 94 1.06 (0.78 to 1.46) 1.07 (0.78 to 1.47)
0.923  0.952 77 1.19 (0.83 to 1.72) 1.15 (0.79 to 1.65)  0.769 0.802 113 1.13 (0.83 to 1.53) 1.15 (0.84 to 1.56)
0.953  0.989 109 1.63 (1.15 to 2.31) 1.54 (1.08 to 2.19)  0.803 0.845 125 1.17 (0.86 to 1.58) 1.19 (0.88 to 1.61)
 0.990 110 1.63 (1.15 to 2.31) 1.51 (1.06 to 2.15)    0.846 160 1.48 (1.10 to 2.00) 1.52 (1.12 to 2.05)
P trend  <.001 .006    P trend  .003 .002
* Number of colon cancer patients. BMI = body mass index; WHR = waist-to-hip ratio.
 Crude model is derived from Cox regression using age as the underlying time variable and strati¿ ed by center and age at recruitment.
  Multivariable models for height and BMI were based on the crude model with additional adjustment for smoking status (never,  past,  current, or unknown),
edu cation (no school degree or primary school, technical or professional school, secondary school, university degree, or unknown), alcohol intake (continuous),
phy  sical  activity  (inactive,  moderately  inactive,  moderately  active,  active,  or  missing),  ¿ ber  intake  (continuous),  and  consumption  of  red  and  processed  meat
(continuous), ¿ sh and shell¿ sh (continuous), and fruits and vegetables (continuous). Multivariable model for weight, waist, hip, and WHR were further adjusted
for height (continuous).
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Table 4.  Relative risks (RRs) and 95% con¿ dence intervals (CIs) of rectal cancer across quintiles of anthropometric measures in the European Prospective











Height, cm Height, cm
<168.0 53 1 (Referent) 1 (Referent)  <156.0 50 1 (Referent) 1 (Referent)
168.0  172.4 74 1.32 (0.91 to 1.90) 1.30 (0.90 to 1.87)  156.0  159.9 61 1.03 (0.70 to 1.51) 1.03 (0.70 to 1.52)
172.5  176.1 57 0.99 (0.67 to 1.47) 0.97 (0.65 to 1.44)  160.0  163.2 83 1.24 (0.86 to 1.80) 1.25 (0.86 to 1.81)
176.2  180.4 59 1.03 (0.69 to 1.52) 1.00 (0.67 to 1.49)  163.3  167.4 53 0.80 (0.53 to 1.21) 0.81 (0.54 to 1.23)
 180.5 52 1.03 (0.68 to 1.56) 1.00 (0.66 to 1.52)    167.5 44 0.77 (0.49 to 1.18) 0.78 (0.50 to 1.21)
P trend  .66 .55    P trend  .09 .12
Weight, kg Weight, kg
<71.0 49 1 (Referent) 1 (Referent)  <56.9 53 1 (Referent) 1 (Referent)
71.0  76.9 59 1.15 (0.78 to 1.68) 1.17 (0.80 to 1.73)  56.9  62.0 45 0.76 (0.51 to 1.14) 0.81 (0.54 to 1.21)
77.0  82.7 57 1.10 (0.75 to 1.62) 1.14 (0.76 to 1.70)  62.1  67.4 60 0.92 (0.63 to 1.34) 1.01 (0.69 to 1.49)
82.8  89.9 67 1.26 (0.87 to 1.83) 1.30 (0.87 to 1.94)  67.5  74.9 67 0.93 (0.64 to 1.34) 1.04 (0.71 to 1.53)
 90.0 63 1.18 (0.81 to 1.73) 1.22 (0.80 to 1.86)    75.0 66 0.92 (0.63 to 1.33) 1.06 (0.71 to 1.57)
P trend  .36 .36    P trend  .94 .44
BMI, kg/m 2  BMI, kg/m2
<23.6 52 1 (Referent) 1 (Referent)  <21.7 47 1 (Referent) 1 (Referent)
23.6  25.3 52 0.89 (0.60 to 1.31) 0.88 (0.60 to 1.30)  21.7  23.5 44 0.77 (0.51 to 1.16) 0.78 (0.51 to 1.18)
25.4  27.0 58 0.98 (0.67 to 1.44) 0.96 (0.66 to 1.40)  23.6  25.7 72 1.11 (0.77 to 1.62) 1.14 (0.78 to 1.66)
27.1  29.3 69 1.15 (0.80 to 1.67) 1.11 (0.77 to 1.62)  25.8  28.8 63 0.92 (0.63 to 1.36) 0.95 (0.64 to 1.41)
 29.4 64 1.12 (0.77 to 1.62) 1.05 (0.72 to 1.55)    28.9 65 1.03 (0.70 to 1.52) 1.06 (0.71 to 1.58)
P trend  .28 .47    P trend  .58 .51
Waist circumference, cm Waist circumference, cm
<86.0 40 1 (Referent) 1 (Referent)  <70.2 40 1 (Referent) 1 (Referent)
86.0  91.8 52 1.09 (0.72 to 1.65) 1.06 (0.70 to 1.61)  70.2  75.8 54 1.08 (0.71 to 1.63) 1.10 (0.73 to 1.66)
91.9  96.5 60 1.18 (0.79 to 1.77) 1.15 (0.76 to 1.73)  75.9  80.9 55 0.91 (0.60 to 1.37) 0.94 (0.62 to 1.42)
96.6  102.9 65 1.23 (0.82 to 1.84) 1.18 (0.78 to 1.77)  81.0  88.9 72 1.18 (0.79 to 1.76) 1.22 (0.82 to 1.83)
 103.0 76 1.37 (0.93 to 2.04) 1.27 (0.84 to 1.91)    89.0 70 1.18 (0.79 to 1.78) 1.23 (0.81 to 1.86)
P trend  .08 .21    P trend  .28 .22
Hip circumference, cm Hip circumference, cm
<95.2 53 1 (Referent) 1 (Referent)  <93.7 49 1 (Referent) 1 (Referent)
95.2  98.9 53 1.07 (0.73 to 1.57) 1.07 (0.73 to 1.58)  93.7  97.9 46 0.92 (0.61 to 1.38) 0.97 (0.65 to 1.46)
99.0  101.9 73 1.12 (0.78 to 1.60) 1.12 (0.78 to 1.61)  98.0  101.9 70 1.05 (0.72 to 1.52) 1.14 (0.78 to 1.66)
102.0  105.9 52 1.18 (0.80 to 1.74) 1.19 (0.79 to 1.78)  102.0  107.9 64 1.16 (0.79 to 1.71) 1.27 (0.86 to 1.88)
 106.0 61 1.07 (0.73 to 1.56) 1.05 (0.70 to 1.56)    108.0 62 1.00 (0.67 to 1.47) 1.10 (0.74 to 1.64)
P trend  .66 .77    P trend  .75 .44
WHR WHR
<0.887 23 1 (Referent) 1 (Referent)  <0.734 41 1 (Referent) 1 (Referent)
0.887  0.922 64 2.15 (1.33 to 3.47) 2.07 (1.28 to 3.35)  0.734  0.768 47 0.90 (0.59 to 1.37) 0.88 (0.58 to 1.34)
0.923  0.952 71 2.17 (1.35 to 3.49) 2.06 (1.28 to 3.32)  0.769  0.802 60 1.03 (0.69 to 1.55) 1.01 (0.68 to 1.52)
0.953  0.989 56 1.62 (0.99 to 2.64) 1.49 (0.91 to 2.45)  0.803  0.845 65 1.07 (0.72 to 1.60) 1.04 (0.69 to 1.56)
 0.990 78 2.17 (1.35 to 3.49) 1.93 (1.19 to 3.13)    0.846 78 1.26 (0.85 to 1.87) 1.20 (0.81 to 1.79)
P trend  .04 .16    P trend  .11 .17
* Number of rectal cancer patients. BMI = body mass index; WHR = waist-to-hip ratio.
 Crude model is derived from Cox regression using age as the underlying time variable and strati¿ ed by center and age at recruitment.
  Multivariable models for height and BMI were based on the crude model with additional adjustment for smoking status (never, past, current, or unknown), educa-
tion (no school degree or primary school, technical or professional school, secondary school, university degree, or unknown), alcohol intake (continuous), physical ac-
tivity (inactive, moderately inactive, moderately active, active, or missing), ¿ ber intake (continuous), and consumption of red and processed meat (continuous), ¿ sh and
shell¿ sh (continuous), and fruits and vegetables (continuous). Multivariable model for weight, waist, hip, and WHR were further adjusted for height (continuous).
 P trend (two-sided) across categories is based on the median anthropometric variable within quintiles as a continuous variable using the Wald chi-square statistic.
cancer risk in men but only weakly related to risk in women. In
contrast, both waist  circumference and WHR were strongly re-
lated to colon cancer  risk in both sexes. Thus,  WHR conveyed
statistically  signi¿ cant  information  beyond  body  weight  for
colon cancer risk in women, but not in men. These data support
the hypothesis that abdominal  obesity is a risk factor for colon
cancer  in  both  sexes  and  suggest  that  fat  distribution  is  more
 important than body weight or BMI for disease risk in women.
 Further,  our  results  indicate  that  the  association  of  body  fat
accumulation and risk of colon cancer in postmenopausal women
may be associated with  HRT use.  That  is,  waist  circumference
and WHR were statistically signi¿ cantly related to risk of colon
cancer among nonusers but not among users of HRT, although the
difference  was only  marginally  statistically  signi¿ cant. Finally,
results  from  our  study  support  the  hypothesis  that  height  is
related to colon cancer risk in both sexes.
 Previous studies have primarily used body weight or BMI to
assess the association of obesity with colon cancer risk. Similar
to our ¿ ndings ( Table 3 ), most of these studies found positive as-
sociations of these measurements for men but weaker or no as-
sociations for women  ( 1  30 ) . However, these measurements may
not  be  ideal  because  the  changes  in  physiologic  functions  that
accompany obesity  depend to  a  certain  extent  on  regional  adi-
pose  tissue  distribution.  Intra-abdominal  visceral  obesity  is  re-
lated  to  elevated  blood  pressure  and  insulin  levels,  insulin
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upper-body  fat  distribution  is  independently  associated  with  a
higher  risk  of  developing  diabetes  and  cardiovascular  disease
( 50 )  .  Higher  body weight  is  more closely related to  abdominal
obesity than to lower-body obesity in men but more closely re-
lated to gluteofemoral obesity in women  (31 )  . Similarly, in our
cohort  WHR was  more  closely  related  to  BMI  in  men  than  in
women.  Hence,  assuming  that  it  is  primarily  visceral  and  not
nonvisceral  adipose  tissue  that  is  involved  in  tumorigenic  pro-
cesses,  body  weight  and  BMI  may  not  accurately  reÀ ect the
colon cancer risk that is associated with abdominal fat accumula-
tion, at least in women.
 Few  prospective  studies  have  examined  the  association  of
body fat  distribution  as  reÀ ected by waist  and  hip circumfer-
ence  and colon  cancer  risk  (11 , 13 , 14 , 19 , 21 , 51 ) . Among these
studies, we are aware of only one report  (21 ) that presented re-
sults  for  men  and  women  separately.  In  this  report,  from  the
Framingham Study  (21 ) , which included 306 colon cancer case
patients,  waist  circumference  was an equally  strong risk factor
for colon cancer in men and women, and it  was a stronger risk
factor than BMI in both sexes. A report from the Cardiovascular
Health Study, which included 102 men and women with colorec-
tal cancer, found that waist circumference and WHR were statis-
tically  signi¿ cantly   related to  risk  of  colorectal  cancer  but  that
BMI was not; however, this analysis did not present sex-speci¿ c
results  (51 ) .
Our ¿ ndings are in contrast with reports from the Melbourne
Collaborative  Cohort  Study   ( 19 )  and  the  Health  Professionals
Follow-up Study  ( 13 ) , which found an association between WHR
and colon cancer risk in men even after adjustment for BMI, and
with reports from the Iowa Women s Health Study  (11 ) and the
Nurses  Health Study  ( 14 ) , which found statistically signi¿ cantly
positive associations in women between BMI but not WHR and
risk of colon cancer. However, most of these studies  (11 , 13 , 14 )
relied on self-reported anthropometric data, which limits the in-
terpretability of these results.
The pathophysiology underlying the association between obe-
sity  and  increased  colon  cancer  risk  is  unclear.  Some  authors
have suggested that components of the metabolic syndrome, par-
ticularly insulin resistance and subsequent hyperinsulinemia, are
the underlying link, which may reÀ ect the growth-promoting ef-
fects of insulin  ( 52  54 ) . These speculations are also supported by
studies that found subjects with type 2 diabetes to be at increased
risk of colon cancer  (55 , 56 ) . Hyperinsulinemia is also related to
increased  levels  of  bioavailable  insulin-like  growth  factor  1,
which is known to have cancer-promoting effects  (57  60 ) . Fur-
ther potential mediators include leptin, which stimulates growth
of  colonic  epithelial  cells   (61  63 )  ,  and  adiponectin,  which  has
antiangiogenic and antitumor activities  ( 64 , 65 ) . We are now ana-
lyzing the relationship of these and other biomarkers with risk of
colon and rectal cancer in EPIC.
 Postmenopausal  HRT has been associated with reduced risk
of colon cancer in observational studies  (33 ) , a ¿ nding that has
been supported by the results  of the Women s Health  Initiative
intervention  trial  of  estrogen  plus  progestin  use   (34  36 ) . HRT
has been hypothesized to reduce the risk of colon cancer by re-
ducing the likelihood of  estrogen receptor methylation  (66 , 67 ) .
In our study we found that, among postmenopausal women, the
positive association of waist circumference and WHR with risk
of  colon  cancer  was not  apparent  in  women who  used HRT at
baseline ( Table 6 ). We are aware of only one case  control study
that has examined the interaction between HRT use and adiposity
on colon cancer risk, with body weight assessed in colon cancer
Table 5.  Relative risk (RRs) and 95% con¿ dence intervals (CIs) of colon cancer across quintiles of waist and hip circumference and waist-to-hip ratio (WHR) after
controlling for body weight in men and women of the European Prospective Investigation into Cancer and Nutrition *
Men Women
Measure Multivariable RR (95% CI) Measure Multivariable RR (95% CI)
Waist circumference, cm Waist circumference, cm
<86.0 1 (Referent)  <70.2 1 (Referent)
86.0  91.8 0.67 (0.46 to 0.98)  70.2 75.8 1.10 (0.79 to 1.53)
91.9  96.5 0.85 (0.59 to 1.23)  75.9 80.9 1.22 (0.87 to 1.70)
96.6  102.9 0.91 (0.61 to 1.35)  81.0 88.9 1.23 (0.85 to 1.77)
 103.0 1.01 (0.62 to 1.65)    89.0 1.44 (0.92 to 2.26)
P trend  .50    P trend  .12
Hip circumference, cm Hip circumference, cm
<95.2 1 (Referent)  <93.7 1 (Referent)
95.2  98.9 0.81 (0.57 to 1.16)  93.7 97.9 0.95 (0.70 to 1.29)
99.0  101.9 0.89 (0.63 to 1.26)  98.0 101.9 1.00 (0.74 to 1.36)
102.0  105.9 0.97 (0.65 to 1.43)  102.0 107.9 0.89 (0.63 to 1.27)
 106.0 0.88 (0.55 to 1.39)    108.0 0.94 (0.60 to 1.46)
P trend  .85    P trend  .72
WHR WHR
<0.887 1 (Referent)  <0.734 1 (Referent)
0.887  0.922 1.08 (0.75 to 1.57)  0.734 0.768 1.06 (0.78 to 1.46)
0.923  0.952 1.02 (0.70 to 1.49)  0.769 0.802 1.13 (0.83 to 1.54)
0.953  0.989 1.32 (0.91 to 1.91)  0.803 0.845 1.16 (0.85 to 1.58)
 0.990 1.18 (0.79 to 1.76)    0.846 1.46 (1.06 to 2.00)
P trend  .27    P trend  .01
 * Multivariable models were derived from Cox regression using age as the underlying time variable and strati¿ ed by center and age at recruitment with additional
adjustment for height (continuous), weight (continuous), smoking status (never, past, current, or unknown), education (no school degree or primary school, technical
or professional school, secondary school, university degree, or unknown), alcohol consumption (continuous), physical activity (inactive, moderately inactive, mod-
erately active, active, or missing), ¿ ber intake (continuous), and consumption of red and processed meat (continuous), ¿ sh and shell¿ sh (continuous), and fruits and
vegetables (continuous).
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patients and population-based control subjects  (20 ) . Contrary to
our ¿ ndings,  in  that  report   (20 )  a  positive  association between
BMI  and  colon  cancer  risk  was  observed  for  postmenopausal
women on HRT only.  The  reasons for  this  discrepancy are  un-
clear; however, differences between HRT users and nonusers in
the association of obesity with postmenopausal breast cancer risk
similar to our observations for colon cancer have previously been
reported  (37 )  .  Because the differences  between HRT users  and
non  users  were  only  marginally  statistically  signi¿ cant  in  our
study, we cannot rule out a role for chance. Clearly, our ¿ ndings
need to be con¿ rmed in future studies and to be put  in context
with  the  complex  effects  observed  in  interventional  studies  of
HRT use on women s health, e.g., their detrimental effects on the
cardiovascular system  (34 ) .
 In  our  analysis,  height  was  related  to  risk  of  colon  cancer
( Table 3 ), a ¿ nding that is in agreement with previous studies  ( 68 ) .
The magnitude of this association was similar in men and women.
Height  has  been  related  to  several  types  of  cancer,  including
 colon, breast, pancreatic, and prostate cancer  (37 , 69 ) , and it was
recently  estimated that  18% of  total  cancers  are  attributable  to
factors related to tallness  (69 ) . Tallness is related to having more
cells in the body structure, which may increase the probability of
malignant transformation  ( 70 ) . Postnatal growth depends largely
on  a  complex  interaction  between  nutrition,  growth  hormones
(GH, insulin-like growth factor), and sex hormones, all of which
have been suggested to be involved in cancer development  (71 ) .
For example, evidence from animal and human studies suggests
that restricted caloric intake in early life is related to lower adult
cancer risk  (72  74 ) . Adult height may also reÀ ect increased ex-
posure  to  GH,  insulin-like  growth  factor  1,  and  insulin  in  pre-
adulthood that may predispose to cancer development in later life
( 57 , 58 , 75 , 76 )  .  These speculations are supported by studies that
found  patients with  GH  excess  (e.g.,  acromegaly)  to  be  at  in-
creased cancer risk, particularly for colon cancer  ( 77 , 78 ) .
In agreement with most previous reports, we found no statisti-
cally signi¿ cant association between body size and risk of rectal
Table 6.  Relative risks (RRs) and 95% con¿ dence intervals (CIs) of colon cancer across quintiles of anthropometric measures in postmenopausal women strati¿ ed
by hormone replacement therapy (HRT) use at baseline in the European Prospective Investigation into Cancer and Nutrition *
No HRT use  HRT use
Measure N  RR (95% CI) N  RR (95% CI)
Weight  , kg
<56.9 48 1 (Referent) 15 1 (Referent)
56.9  62.0 56 1.05 (0.71 to 1.56) 16 1.04 (0.50 to 2.18)
62.1  67.4 61 0.99 (0.67 to 1.46) 15 0.95 (0.44 to 2.03)
67.5  74.9 82 1.08 (0.74 to 1.57) 23 1.55 (0.74 to 3.22)
 75.0 89 1.13 (0.77 to 1.67) 12 1.01 (0.43 to 2.37)
P trend  .49 .69
BMI, kg/m 2
<21.7 40 1 (Referent) 21 1 (Referent)
21.7  23.5 50 0.96 (0.63 to 1.45) 15 0.69 (0.35 to 1.35)
23.6  25.7 77 1.21 (0.82 to 1.78) 17 0.80 (0.41 to 1.56)
25.8  28.8 83 1.11 (0.75 to 1.64) 20 1.10 (0.57 to 2.10)
 28.9 86 1.12 (0.75 to 1.67) 8 0.72 (0.31 to 1.70)
P trend  .52 .88
Waist circumference  , cm
<70.2 25 1 (Referent) 17 1 (Referent)
70.2  75.8 48 1.30 (0.80 to 2.11) 21 1.07 (0.55 to 2.06)
75.9  80.9 71 1.35 (0.85 to 2.14) 17 0.79 (0.39 to 1.57)
81.0  88.9 85 1.39 (0.88 to 2.19) 17 0.90 (0.44 to 1.83)
 89.0 106 1.68 (1.06 to 2.64) 9 0.76 (0.32 to 1.80)
P trend  .02 .46
Hip circumference  , cm
<93.7 43 1 (Referent) 23 1 (Referent)
93.7  97.9 46 0.93 (0.61 to 1.41) 17 0.71 (0.37 to 1.36)
98.0  101.9 88 1.21 (0.83 to 1.76) 13 0.43 (0.21 to 0.88)
102.0  107.9 68 1.04 (0.70 to 1.54) 14 0.70 (0.34 to 1.44)
 108.0 89 1.08 (0.74 to 1.60) 13 0.77 (0.37 to 1.61)
P trend  .69 .54
WHR 
<0.734 27 1 (Referent) 19 1 (Referent)
0.734  0.768 40 1.02 (0.62 to 1.66) 19 0.79 (0.41 to 1.53)
0.769  0.802 75 1.55 (1.00 to 2.42) 11 0.46 (0.21 to 0.99)
0.803  0.845 85 1.51 (0.97 to 2.34) 14 0.69 (0.34 to 1.43)
 0.846 107 1.76 (1.14 to 2.72) 17 0.96 (0.47 to 1.94)
P trend  .002 .89
* Relative risks derived from multivariable Cox regression models using age as the underlying time variable and strati¿ ed by center and age at recruitment with ad-
ditional adjustment for smoking status (never, past, current, or unknown), education (no school degree or primary school, technical or professional school, secondary
school, university degree, or unknown), alcohol consumption (continuous), physical activity (inactive, moderately inactive, moderately active, active, or missing),
¿ ber intake (continuous), and consumption of red and processed meat (continuous), ¿ sh and shell¿ sh (continuous), and fruits and vegetables (continuous). BMI =
body mass index; WHR = waist-to-hip ratio.
 Number of colon cancer patients.
 Relative risks for weight, waist and hip circumference, and WHR are also adjusted for height (continuous).
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cancer ( Table 4 )  (2  5 , 12 , 17 , 27 , 30 ) . This ¿ nding suggests differ-
ences in tumor susceptibility between colon and rectum, although
the potential mechanisms accounting for these differences need
further investigation.
 Our study has strengths and limitations. Among the strengths
are its  prospective  design  and the large  sample  size,  which in-
cluded several European countries. Also, all body measures were
assessed directly at baseline, in contrast to self-reported data used
in most previous studies. Among the limitations were slight dif-
ferences in the method of assessment of waist and hip circumfer-
ence between centers in EPIC; however, we found similar results
for  the  associations  of  body  size  with  risk  of  colon  and  rectal
cancer  across  centers,  which also reduces  the possibility  of  re-
sidual  confounding  by  geographic  region.  The  combination  of
related measures in our analysis may lead to imprecision and in-
stability  of  the risk  estimates;  however,  the  width  of  the con¿ -
dence intervals did not substantially change when we combined
body weight with waist or hip circumference or WHR, therefore
indicating that these combinations did not substantially decrease
precision. Nevertheless, the anthropometric parameters we used 
although being standard, well established, and routinely used for
disease  risk  assessment   may  be  imperfect  measures  of  body
size  or  underlying  true  biologic  risk  factors,  and  this  situation
may complicate the interpretation of our ¿ ndings when consider-
ing these measures simultaneously.
Within EPIC we currently have standardized information about
exposure  variables  available  at  baseline  only,  which  neglects
modi¿ cations  in  subjects  exposure  status  during  follow-up.
 However,  any  potential  misclassi¿  cation  should  be  nondif-
ferential and, if anything, is expected to bias our results toward
the null.
 Information  on  menopausal  status  was  available  at  baseline
only; we were therefore unable to stratify our analysis by meno-
pausal status at time of cancer diagnosis. Previous studies have
suggested that the association of BMI with risk of colon cancer
may be  stronger  in,  or  even  limited  to,  premenopausal  women
( 20 , 23 , 79 ) . In our analysis, only 33% of women were premeno-
pausal at baseline; it is therefore reasonable to assume that most
women were postmenopausal (or at least perimenopausal) at the
time of cancer diagnosis. In line with this hypothesis, when we
restricted  the  analysis  to  women  who  were  postmenopausal  at
baseline,  our  ¿ ndings  were  almost  identical  to  those  using  all
women.  Although  our  study  included  many  colon  cancer  case
patients, strati¿ cation may have limited the power to detect sta-
tistically signi¿ cant associations of waist circumference or WHR
with  risk  of  colon  cancer  among  postmenopausal  women  with
HRT  use.  However,  in  this  group  the  point  estimates  of  risk
showed no substantial variation across quintiles of measures of
obesity, arguing against a substantial association with colon can-
cer risk. Despite excluding participants with reported cancers at
baseline,  we  cannot  exclude  the  possibility  that  some  subjects
had underlying yet undiagnosed colon or rectal cancer. However,
results  did  not  appreciably  change  when we  excluded  subjects
with a follow-up time of less than 2 years.
 In conclusion, in this study we found that abdominal obesity
is  an  equally  strong  risk  factor  for  colon  cancer  in  men  and
women, whereas body weight and BMI were associated with co-
lon cancer risk in men but not in women. These data suggest that
fat distribution is a more important risk factor than body weight
and  BMI  for  colon  cancer  in  women.  Also,  our  study suggests
that the relationship between abdominal obesity and colon cancer
risk may vary according to HRT use; however, these ¿ ndings re-
quire  con¿ rmation  in  future  studies.  Our data  give  further  cre-
dence to public health efforts aiming to reduce the prevalence of
obesity  to prevent cancer and other chronic diseases.  Measure-
ment of waist circumference or WHR should be included in cur-
rent  guidelines  to  maintain  a  healthful  lifestyle  for  disease
prevention  ( 80 ) .
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